Clinical characteristics of patients with RA treated with adalimumab
| Variables | Switchers | Controls |
|---|---|---|
| (n = 24) | (n = 25) | |
| DMARD, disease modifying antirheumatic drug. | ||
| Age (years), mean (SD) | 56.7 (11.2) | 55.9 (10.8) |
| Female, No (%) | 22 (92) | 22 (88) |
| Disease duration (years), mean (SD) | 16.6 (7.0) | 15.8 (7.5) |
| Seropositivity, No (%) | 15 (63) | 16 (64) |
| DAS28, mean (SD) | 5.6 (0.8) | 5.9 (0.9) |
| DMARD treatment, No (%) | 24 (100) | 25 (100) |
| Methotrexate | 20 (83) | 22 (88) |
| Ciclosporin | 1 (4) | – |
| Leflunomide | 3 (13) | 3 (12) |
| Prednisone treatment, No (%) | 24 (100) | 25 (100) |
| Prednisone dosage (mg/day), mean (SD) | 6.8 (2.1) | 7.0 (2.5) |